Table 1 Current and potential future chemotherapeutic options for pancreatic ductal adenocarcinoma

Mitomycin C^a

Patients with mutations in PALB2

-

[61]

Olaparib^a

Patients with mutations in BRCA2

-

[68, 69]

Gemcitabine alone

All

5.65-7.2 months^b

[9, 90–94]

Gemcitabine + cisplatin

All

7.5 months

[91]

Gemcitabine + erlotinib

All

6.2 months

[10]

Gemcitabine + capecitabine

All

7.1-8.4 months^b

[93, 94]

Gemcitabine + docetaxel + capecitabine (GTX)^a

All

-

[95]

Gemcitabine + Nab-paclitaxel

All

12.2 months

[11]

Folinic acid + fluorouracil + irinotecan + oxaliplatin (FOLFIRINOX)

All

11.1 months

[90]